Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10637388rdf:typepubmed:Citationlld:pubmed
pubmed-article:10637388lifeskim:mentionsumls-concept:C0175649lld:lifeskim
pubmed-article:10637388lifeskim:mentionsumls-concept:C0596545lld:lifeskim
pubmed-article:10637388lifeskim:mentionsumls-concept:C0439234lld:lifeskim
pubmed-article:10637388pubmed:issue6lld:pubmed
pubmed-article:10637388pubmed:dateCreated2000-2-10lld:pubmed
pubmed-article:10637388pubmed:abstractTextTwo hundred and two patients (97 female and 105 male; mean age: 45. 5+/-9 years) received CarboMedics bileaflet valves during a period of eight years. Ninety-one patients received mitral, 72 aortic and 39 aortic+mitral valve prosthesis. Tricuspid plasty and coronary artery bypass surgery were the concomitant operations in 17 and 12 patients, respectively. The mean follow-up period was 24.7 months and the ratio was 91%. Overall operative mortality was 3.96% (8 patients); 2.78% for aortic valve replacement (AVR), 3.29% for mitral valve replacement (MVR) and 7.7% for double valve replacement (DVR). The late mortality rate was 2.89% for AVR, 2.2% for MVR and 8. 3% for DVR. The main cause of mortality was low cardiac output. The overall survival rate was 91.5% in 2 years. The actuarial freedom from thromboembolism in 2 years was 97% for AVR, 95% for MVR and 84% for DVR. No mortality due to heamorrhagic events was observed. CarboMedics prosthetic heart valves may be used satisfactorily with a low incidence of valve-related morbidity and mortality.lld:pubmed
pubmed-article:10637388pubmed:languageenglld:pubmed
pubmed-article:10637388pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10637388pubmed:citationSubsetIMlld:pubmed
pubmed-article:10637388pubmed:statusMEDLINElld:pubmed
pubmed-article:10637388pubmed:monthDeclld:pubmed
pubmed-article:10637388pubmed:issn1341-1098lld:pubmed
pubmed-article:10637388pubmed:authorpubmed-author:SonculHHlld:pubmed
pubmed-article:10637388pubmed:authorpubmed-author:SinciVVlld:pubmed
pubmed-article:10637388pubmed:authorpubmed-author:KalayciogluSSlld:pubmed
pubmed-article:10637388pubmed:authorpubmed-author:GokgozLLlld:pubmed
pubmed-article:10637388pubmed:authorpubmed-author:HalinPPlld:pubmed
pubmed-article:10637388pubmed:authorpubmed-author:GunaydinSSlld:pubmed
pubmed-article:10637388pubmed:authorpubmed-author:ImrenYYlld:pubmed
pubmed-article:10637388pubmed:authorpubmed-author:EesozAAlld:pubmed
pubmed-article:10637388pubmed:issnTypePrintlld:pubmed
pubmed-article:10637388pubmed:volume5lld:pubmed
pubmed-article:10637388pubmed:ownerNLMlld:pubmed
pubmed-article:10637388pubmed:authorsCompleteYlld:pubmed
pubmed-article:10637388pubmed:pagination382-6lld:pubmed
pubmed-article:10637388pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:10637388pubmed:meshHeadingpubmed-meshheading:10637388...lld:pubmed
pubmed-article:10637388pubmed:meshHeadingpubmed-meshheading:10637388...lld:pubmed
pubmed-article:10637388pubmed:meshHeadingpubmed-meshheading:10637388...lld:pubmed
pubmed-article:10637388pubmed:meshHeadingpubmed-meshheading:10637388...lld:pubmed
pubmed-article:10637388pubmed:meshHeadingpubmed-meshheading:10637388...lld:pubmed
pubmed-article:10637388pubmed:meshHeadingpubmed-meshheading:10637388...lld:pubmed
pubmed-article:10637388pubmed:meshHeadingpubmed-meshheading:10637388...lld:pubmed
pubmed-article:10637388pubmed:meshHeadingpubmed-meshheading:10637388...lld:pubmed
pubmed-article:10637388pubmed:meshHeadingpubmed-meshheading:10637388...lld:pubmed
pubmed-article:10637388pubmed:meshHeadingpubmed-meshheading:10637388...lld:pubmed
pubmed-article:10637388pubmed:meshHeadingpubmed-meshheading:10637388...lld:pubmed
pubmed-article:10637388pubmed:meshHeadingpubmed-meshheading:10637388...lld:pubmed
pubmed-article:10637388pubmed:meshHeadingpubmed-meshheading:10637388...lld:pubmed
pubmed-article:10637388pubmed:meshHeadingpubmed-meshheading:10637388...lld:pubmed
pubmed-article:10637388pubmed:meshHeadingpubmed-meshheading:10637388...lld:pubmed
pubmed-article:10637388pubmed:meshHeadingpubmed-meshheading:10637388...lld:pubmed
pubmed-article:10637388pubmed:meshHeadingpubmed-meshheading:10637388...lld:pubmed
pubmed-article:10637388pubmed:meshHeadingpubmed-meshheading:10637388...lld:pubmed
pubmed-article:10637388pubmed:meshHeadingpubmed-meshheading:10637388...lld:pubmed
pubmed-article:10637388pubmed:meshHeadingpubmed-meshheading:10637388...lld:pubmed
pubmed-article:10637388pubmed:meshHeadingpubmed-meshheading:10637388...lld:pubmed
pubmed-article:10637388pubmed:meshHeadingpubmed-meshheading:10637388...lld:pubmed
pubmed-article:10637388pubmed:meshHeadingpubmed-meshheading:10637388...lld:pubmed
pubmed-article:10637388pubmed:year1999lld:pubmed
pubmed-article:10637388pubmed:articleTitleEight year experience with the CarboMedics bileaflet valvular prosthesis.lld:pubmed
pubmed-article:10637388pubmed:affiliationDepartment of Thoracic and Cardiovascular Surgery, Gazi University School of Medicine, Ankara, Turkey.lld:pubmed
pubmed-article:10637388pubmed:publicationTypeJournal Articlelld:pubmed